Described herein are compositions and methods of treating a cardiac condition using modified placental tissue or an extract of a placental tissue, capable of recruiting stem cells or promoting healing in vivo and in vitro.

Methods for treating radiation or chemical injury are described that comprise administering to a subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described.

An object of the present invention is to provide a method for cryopreserving rat sperms and an in vitro fertilization method using cryopreserved rat sperms. The present invention provides a method for preparing cryopreserved rat sperms, characterized by comprising the following steps: step a: a preparation step of collecting rat sperms from the rat cauda epididymis to prepare a sperm suspension, step b: a cooling step of cooling the sperm suspension to about 1° C. or lower, and step c: a freezing step of freezing the rat sperm suspension cooled to about 1° C. or lower.

The present invention provides an endodermal cell production method that can induce differentiation of pluripotent cells into endodermal cells even when the pluripotent cells are dispersed and can achieve improved endodermal cell production efficiency. The endodermal cell production method according to the present invention is a method for producing endodermal cells by inducing differentiation of pluripotent cells into the endodermal cells, including the step of: inducing differentiation of the pluripotent cells into the endodermal cells in the presence of an endodermal cell inducing factor. In the induction step, the cell density of the pluripotent cells at the start of the induction preferably is from 0.5×10.sup.4 to 2×10.sup.4 cells/cm.sup.2.

The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.

Certain embodiments provide a method of producing a population of induced multipotent placental cells, the method comprising culturing a population of pluripotent stem cells in the presence of an induction media comprising a retinoid, and optionally a Wnt signaling agonist. Certain embodiments also provide cells, compositions, kits and methods of use thereof.

Described herein is a method for producing a chimeric non-human animal expressing a human ETV2 gene comprising: a) generating an ETV2 null non-human animal cell, wherein both copies of the non-human ETV2 gene carry a mutation that prevents production of functional ETV2 protein in said non-human animal; b) creating an ETV2 null non-human blastocyst by somatic cell nuclear transfer comprising fusing a nucleus from said ETV2 null non-human animal cell of a) into an enucleated non-human oocyte and activating said oocyte to divide so as to form an ETV2 null non-human blastocyst; c) introducing human stem cells into the ETV2 null non-human blastocyst of b); and d) implanting said blastocyst from c) into a pseudopregnant surrogate non-human animal to generate a chimeric non-human animal expressing human ETV2.

The present disclosure provides compositions and methods employing stem cell-derived amnion tissue. In some embodiments, compositions (e.g., scaffolds and devices) and methods of generating amnion-like tissues from hPSCs are provided. In some embodiments, uses of such cells for research, compound screening and analysis, and therapeutics are provided.

A compound and methods are provided for treating, preventing or ameliorating infertility or reduced fertility in an individual, wherein said compound is capable of regulating the activity of Nuclear Factor, Erythroid 2 Like 2 (NFE2L2).

A method for making an at least double layered cell aggregate and/or an artificial blastocyst, and/or a further-developed blastoid termed blastoid, by forming a double layered cell aggregate from at least one trophoblast cell and at least one pluripotent and/or totipotent cell, and culturing the aggregate to obtain an artificial blastocyst having a trophectoderm-like tissue that surrounds a blastocoel and an inner cell mass-like tissue. The cell aggregate can be formed from toti- or pluripotent stem cell types, or induced pluripotent stem cell types, in combination with trophoblast stem cells. Formation of a blastoid can be achieved by culturing the cell aggregate in a medium preferably comprising one or more of a Rho/ROCK inhibitor, a Wnt pathway modulator, a PKA pathway modulator, a PKC pathway modulator, a MAPK pathway modulator, a STAT pathway modulator, an Akt pathway modulator, a Tgf pathway modulator and a Hippo pathway modulator. Also, a method for growing an at least double layered cell aggregate into an artificial blastocyst, and into a further-developed blastoid, a foetus or a live animal and an in vitro cell culture comprising the mentioned compounds and/or cell aggregates.